A rough calculation of revenue potential for CF drugs that can treat most CF patients: 30,000 patients in U.S. and about another 30,000 in europe. Assume Vertex can treat only half these patients and the average cost is $100, 000 per year. 30,000 X $100,000 = 3 billion per year!
Of course, until Vertex has drugs that effectively treat most CF patients, this 3 billion figure will not be realized. However, if just half the 2200 patients that can benefit from Kayleideco pay $200,000/year, then the revenue is 1100 X $200,000 = 220 million per year or $1 per share.